Skip to content
Triangle logo TriangleGet started
← Study library

NCT00750815 · REGISTRY CONDITION SEARCH

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2014-01-20

Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD). The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe dose of the study drugs taken together that a patient can tolerate, and how long it takes for multiple myeloma patients to respond after they have taken the study drugs and how long the response lasts.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase I - Maximum Planned Dose (MPD) Level

→

outcome · POSTED

Phase II: Overall Response Rate (ORR)

→

outcome · POSTED

Phase II: Progression-Free Survival (PFS)

→

outcome · POSTED

Phase II: Two Year Overall Survival (OS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Understand and voluntarily sign informed consent form; equal to or greater than 18 years of age at time of consent * Able to adhere to the study visit schedule and other protocol requirements * Diagnosed active multiple myeloma * Measurable myeloma paraprotein levels in serum (≥ 0.5 g/dL) or urine (≥ 0.2 g excreted in a 24-hour urine collection sample), or serum involved free light chains ( \>10mg/dl) provided that the k/l ratio is abnormal * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Performance status of 3 allowed if related to bony disease. * Bilirubin ≤ 1.5x upper limits of normal (ULN) * Liver enzymes: alanine transaminase (ALT)or aspartic transaminase (AST) ≤ 2.5 x ULN. In the presence of liver metastases, AST / ALT, alkaline phosphatase and total bilirubin must not exceed 3x upper limit of normal (i.e.: must be ≤ 3x ULN). * Adequate bone marrow function: * Absolute neutrophil count (ANC) ≥ 1,000 cells/mm³ (1.0 x 10\^9/L). Patients with bone marrow \>50% plasma cells are permitted to have a neutrophil count of \< 1,000 cells/mm³. * Platelets ≥ 100,000 cells/mm³. Patients with bone marrow \>50% plasma cells are permitted to have a Platelet count ≤ 100, 000 cells/mm³ * Hemoglobin \> 8 g/dL (transfusion allowed to increase the Hgb) * Adequate renal function: Creatinine ≤ 2.5 mg/dL * Must have 2-d echocardiogram or multigated acquisition (MUGA) scan indicating left ventricular ejection fraction (LVEF) ≥ 50% within 42 days prior to first dose of study drug. A MUGA scan or 2- d Echocardiogram may be used, but the same test must be used throughout study) to evaluate LVEF. * Women of childbearing potential(WCBP)† must have negative serum or urine pregnancy test 10 to 14 days prior to starting therapy. Patients with reproductive potential must use an adequate contraceptive method during treatment and for 3 months after completing treatment. In addition, sexually active WCBP must agree to use adequate contraceptive methods per the requirements outlined in protocol document. * Patients treated with local radiotherapy with or without concomitant exposure to steroids, for pain control or management of cord/nerve root compression, are eligible. 4 weeks must have lapsed since last date of radiotherapy. Patients who require concurrent radiotherapy should have entry to the protocol deferred until radiotherapy is completed and 4 weeks have passed since last date of therapy. Exclusion Criteria: * Ongoing severe infection requiring intravenous antibiotic treatment * Life expectancy \< 3 months * Prior malignancy, except; adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the participant has been disease-free for at least 5 years. Concurrent prostate cancer for which patient is receiving therapy will not be considered an exclusion if prostatic specific antigen (PSA) has been stable for 3 years. * Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia * Patients receiving therapeutic dosages of steroids for multiple myeloma * Myocardial infarct within 6 months before enrollment, New York Heart Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities * Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form * Pregnant or breast-feeding females. Lactating females must agree not to breast-feed. * Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Prior chemotherapy for multiple myeloma, except for radiation to symptomatic bony disease, plasmapheresis for hyperviscosity, kyphoplasty and/or vertebroplasty * History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HC1) or the components of DOXIL® * Prior anthracycline dose exceeding 360 mg/m² for doxorubicin (including DOXIL) or 720 mg/m² for epirubicin * Grade 2 or higher peripheral neuropathy on clinical examination within 14 days before enrollment * Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome or plasma cell leukemia * Hypersensitivity to bortezomib, boron or mannitol * Has received other investigational drugs within 14 days before enrollment
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Dose of Cyclophosphamide to depend on how many patients we treated: * Dose Level 1: Cyclophosphamide 250 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12 * Dose Level 2: Cyclophosphamide 500 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12 * Dose Level 3: Cyclophosphamide 750 mg /m\^2 IV Day 1; VELCADE, 1.0 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12 * Dose Level 4: Cyclophosphamide 750 mg /m\^2 IV Day 1; VELCADE, 1.3 mg/m\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12
    intervention Names
    1. Drug: Cyclophosphamide
    2. Drug: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
    label
    A. Phase I - Dose Escalation
    type
    EXPERIMENTAL
  2. description
    Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
    intervention Names
    1. Drug: Cyclophosphamide
    2. Drug: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
    label
    B. Phase II - Maximum Planned Dose (MPD)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. A. Phase I - Dose Escalation
    2. B. Phase II - Maximum Planned Dose (MPD)
    description
    Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
    name
    Cyclophosphamide
    other Names
    1. Cytoxan
    type
    DRUG
  2. arm Group Labels
    1. A. Phase I - Dose Escalation
    2. B. Phase II - Maximum Planned Dose (MPD)
    description
    Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
    name
    Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
    other Names
    1. VELCADE
    2. DOXIL®
    3. PLD
    4. CVDD
    5. VDD
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
58
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Maximum Phase II planned dose of cyclophosphamide when given in combination with bortezomib, pegylated liposomal doxorubicin and Dexamethasone (CVDD) in participants with newly diagnosed active multiple myeloma. Dose levels 1, 2, 3, 4 as outlined in Treatment Arm A. If no dose limiting toxicity (DLT) was reported in the first 3 participants at a dose level, that dose level was to be considered safe and 3 participants would be enrolled at the next dose level. If 1/3 participants in a cohort at a dose level had dose limiting toxicity (DLT), the dose level would be expanded to obtain 6 evaluable participants. MPD reflects the highest dose of drug that did not cause a DLT in 33% of participants.
    measure
    Phase I - Maximum Planned Dose (MPD) Level
    time Frame
    9 months
  2. description
    Best response to CVDD chemotherapy. Overall Response: Partial Response (PR) + Very Good Partial Response (VGPR) + Complete Response (CR). PR: ≥ 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein with urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.
    measure
    Phase II: Overall Response Rate (ORR)
    time Frame
    Up to 6 months
secondary Outcomes
  1. description
    Progression-free survival after CVDD in participants with newly diagnosed active multiple myeloma. PFS: time from the initiation of therapy to progression, relapse or death from any causes. Progressive Disease (PD): Progressive Disease requires any one or more of the following: Increase of ≥ 25% from baseline in: * serum M-component and /or (the absolute increase must be ≥ 0.5 g/dL) * urine M-component and/or (the absolute increase must be ≥ 200 mg/24 h)
    measure
    Phase II: Progression-Free Survival (PFS)
    time Frame
    Up to 50.9 months
  2. description
    Overall survival by disease risk stratification after CVDD. OS: time from initiation of therapy until death from any cause.
    measure
    Phase II: Two Year Overall Survival (OS)
    time Frame
    2 years
Full study description
brief Summary
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD). The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe dose of the study drugs taken together that a patient can tolerate, and how long it takes for multiple myeloma patients to respond after they have taken the study drugs and how long the response lasts.
detailed Description
The first cohort of 3 participants enrolled into Phase I of the study will receive dose level 1. A full safety evaluation will be conducted when these participants have completed one cycle (21 days) of combination therapy. Further patient accrual will be suspended while the safety data is evaluated at each dose level. Dose escalation for subsequent patients will proceed through dose levels 2, 3 and 4 as follows: * If no dose limiting toxicity (DLT) is reported in the first 3 participants at a dose level, that dose level will be considered safe and 3 participants will be enrolled at the next dose level. If 1/3 participants in a cohort at a dose level has a DLT, the dose level will be expanded to obtain 6 evaluable participants. * If \> 1 of 3 participants in a cohort experience DLT, that dose level will not be considered safe. No further dose escalation will take place, and the immediate lower dose level will be considered the maximum planned dose (MPD) if 6 patients had been enrolled at that dose level. Otherwise, expand the immediate lower dose level to 6 evaluable patients\*. * If there are \< 2 participants with a DLT among the expanded cohort of 6 evaluable participants, a cohort of 3 participants will be enrolled in the next higher dose level. * If there are 2 or more participants with a DLT among the expanded cohort of 6 evaluable participants, that dose level will not be considered safe. No further dose escalation will take place, and the immediate lower dose level will be considered the MPD if 6 patients had been enrolled at that dose level. Otherwise, expand the immediate lower dose level to 6 evaluable patients\*. * \* If DLT occurs in no more than 1 patient in the expanded dose cohort, then that dose level will be considered MPD. Otherwise, the dose will be further de-escalated in a similar fashion until the MPD is reached.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0f21dc494980de0621ea
      requested nct id
      NCT00750815
      primary nct id
      NCT00750815
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      7d7837363a5b2219f9410025158513836ff1c069cec6a7225998661f1c44d8f8
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0f21dc494980de0621ea
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00750815
      occurrences
      1. context exact
        NCT00750815
        end
        11
        exact text
        NCT00750815
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/674/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6694c198c9f811d1ade114b085086aec1caf66a728f635afcf60e8cc4af29aa1

    Preserved source evidence · Not medical advice